Top Diversified Bank Stocks To Buy For 2014

“This is a business built by and for baby boomers, but that won’t last long.”

In his presentation to broker-dealer executives at the Financial Services Institute’s OneVoice conference in Washington, Mark Tibergien spoke those words midway through his speech, making explicit what was an underlying theme at the broker-dealer advocacy group’s annual conference.

In a conference that celebrated FSI’s “Decade of Success,” there was some looking back at where the independent broker-dealer business has come from, but there was much more focus on the future. Among the issues: where is the next generation of advisors to come from? Will IBDs’ business model allow for attracting and retaining younger advisors? Will regulatory and market pressures allow BD reps to serve younger clients who may not yet possess wealth? How can you build a business for future success when so many of your advisors and their clients are in or nearing — or should be planning — retirement?

Top 5 Information Technology Stocks To Invest In Right Now: Asante Gold Corp (ASE)

Asante Gold Corporation is a mineral exploration company involved in the acquisition and assessment of mineral properties in the Republic of Ghana. The Company is a gold royalty, exploration and development company. The Company is focused in Ghana, West Africa where it is exploring the Fahiakoba concession, a 22.07 square kilometers prospecting license located on strike with and between Perseus Mining's 4.32 million ounce Edikan Mine and AngloGold Ashanti's 60 million ounce Obuasi mine. It has a 100% interest in the Fahiakoba concession. ASG Mining Ltd. is the Company�� 100% owned Ghana subsidiary. Advisors' Opinion:

• [By Namitha Jagadeesh]

  Greece�� ASE Index (ASE) retreated 4 percent today, pulled down by shares of lenders. National Bank of Greece SA tumbled 27 percent to 1.15 euros after announcing details of a share sale. Piraeus Bank SA slid 21 percent to 36 euro cents.

Top Diversified Bank Stocks To Buy For 2014: First Financial Bankshares Inc.(FFIN)

First Financial Bankshares, Inc., through its subsidiaries, provides commercial banking products and services primarily in Texas. It offers commercial banking services, which include accepting and holding checking, savings, and time deposits, as well as automated teller machines, drive-in and night deposit services, safe deposit facilities, remote deposit capture services, Internet banking, transmitting funds, and other commercial banking services. The company also provides commercial, financial, agricultural, real estate construction, real estate mortgage, and consumer loans to businesses, professionals, individuals, and farm and ranch operations. In addition, it involves in the administration of various types of retirement and employee benefit accounts, which include 401(k) profit sharing plans and IRAs; and offers personal trust services that comprise the administration of estates, testamentary trusts, revocable and irrevocable trusts, and agency accounts. Further, the company offers securities brokerage services. As of December 31, 2009, it operated 48 financial centers in Texas, including 10 locations in Abilene, 2 locations in Cleburne, 3 locations in Stephenville, 3 locations in Granbury, 2 locations in San Angelo, and 3 locations in Weatherford, as well as 1 location each in Mineral Wells, Hereford, Sweetwater, Eastland, Ranger, Rising Star, Southlake, Aledo, Willow Park, Brock, Alvarado, Burleson, Keller, Trophy Club, Boyd, Bridgeport, Decatur, Roby, Trent, Merkel, Clyde, Moran, Albany, Midlothian, and Glen Rose. The company was founded in 1956 and is based in Abilene, Texas.

Advisors' Opinion:

• [By David Hanson and Matt Koppenheffer]

  In the following video, Motley Fool financial analysts David Hanson and Matt Koppenheffer discuss two stocks from the financial sector that they're watching today. David tells us why he's got his eye on�JPMorgan� (NYSE: JPM  ) and the trials and tribulations of CEO Jamie Dimon and what he'll be looking for at the company's annual meeting in two weeks. Matt Koppenheffer discusses the smaller-cap�First Financial Bankshares (NASDAQ: FFIN  ) �and why if Warren Buffett only had $1 million to invest, this might be one of the first places he'd look.

• [By Profit Fan]

  After rising 67% in the past 52-weeks, it is understandable that the price targets for First Financial Bankshares (FFIN) are slightly under the bank's current market price of $57.69 per share. But, the premium paid for these shares appear to be warranted.

• [By John Udovich]

  Texas has set another record for job creation�with small cap Texas banking stock like Texas Capital Bancshares (NASDAQ: TCBI), ViewPoint Financial Group (NASDAQ: VPFG) and First Financial Bankshares (NASDAQ: FFIN) naturally being well positioned to take advantage of the Texas economic miracle (see my previous article: Texas is Booming and So Are These Texas Stocks (EE, TPL & ATO)). I should�add that I wrote about�these Texas banking stocks back in late 2012�(see: Don�� Mess With Texas Banking Stocks TCBI, VPFG & FFIN) and the Texas Workforce Commission has just�reported that the Texas economy added 36,400 jobs in September while over the past 12 months, employers added 413,700 jobs ��the most ever recorded by the state. Moreover, several companies surveyed by the Dallas Fed responded by saying�they are seeing labor market tightness�while companies are saying they are experiencing upward wage pressures�and�staffing�firms�note that�candidates are often receiving multiple offers.

Top Diversified Bank Stocks To Buy For 2014: Gleacher & Company Inc.(GLCH)

Gleacher & Company, Inc., an independent investment bank, provides corporate and institutional clients with advice and execution in the areas of advisory services, capital raising and research, sales, and trading. It operates through five segments: Mortgage Backed/Asset Backed & Rates (MBS/ABS & Rates), Corporate Credit, Investment Banking, Equities, and Other. The MBS/ABS & Rates segment provides sales, trading, banking, research, and advisory services on a range of mortgage and asset-backed securities; the United States Treasury and government agency securities; and structured products, such as collateralized loan obligations and collateralized debt obligations, whole loans, and other securities. The Corporate Credit segment offers analysis, sales, and trading on various debt securities comprising bank debt and loans, investment grade debt, high-yield debt, treasuries, convertibles, distressed debt, preferred debt, emerging markets debt, and reorganization equities to co rporate and institutional investor clients. The Investment Banking segment provides financial advisory services in regards to mergers and acquisitions, restructurings, recapitalizations, and capital markets-related matters. It engages in capital raising through underwritings and private placements of equity and debt securities. The Equities segment offers research on customer trades in equity securities in aerospace, defense, industrials, technology, healthcare, and REIT sectors. The Other segment provides early stage growth capital to companies in the information and energy technology sectors. The company was formerly known as Broadpoint Gleacher Securities Group, Inc. Gleacher & Company, Inc. was founded in 1952 and is headquartered in New York, New York.

Advisors' Opinion:

• [By Eric Volkman]

  The upper ranks of Gleacher (NASDAQ: GLCH  ) management have seen a major shake-up. The financial services company has relieved both CEO Thomas Hughes, and COO John Griff, of their jobs. In a tersely worded filing with the Securities and Exchange Commission, it said that the twin terminations were effective immediately. It provided no reason for its actions.

• [By Eric Volkman]

  Investment bank Gleacher (NASDAQ: GLCH  ) has announced that it will exit its mortgage-backed securities and rates business, as well as its credit-products operations. This move, the repercussions of which could potentially affect up to roughly 160 employees, is effective immediately.

Top Diversified Bank Stocks To Buy For 2014: Blue Water Global Group Inc (BLUU)

Blue Water Global Group, Inc. (Blue Water), incorporated on March 3, 2011, is a development-stage company. The Company focuses on developing a chain of casual dining restaurants in tourist destinations throughout the Caribbean region. The Company's initial restaurant is going to be called Blue Water Bar & Grill and will be located in St. Maarten, Dutch West Indies.

As of February 7, 2013, the Company did not operate any restaurant properties, and did not have any ownership or leaseholds in any restaurant properties. As of February 7, 2013, the Company did not have any ownership or leaseholds in any restaurant properties.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks Caribbean International Holdings (OTCMKTS: CIHN), Blue Water Global Group Inc (OTCBB: BLUU) and Metrospaces Inc (OTCMKTS: MSPC) have been getting some attention lately in various investment newsletters and all three have focused their activities in the Caribbean or South America. However, all three have been the subject of paid promotions which have helped to get them mentions in various investment newsletters. With that in mind, will bets on the Caribbean or South America pay off big for these three small cap stocks and their investors? Here is a quick reality check:

• [By Peter Graham]

  Last Friday, small cap Digital Brand Media & Marketing Group Inc (OTCMKTS: DBMM) surged 22.22% while Blue Water Global Group Inc (OTCBB: BLUU) sank 18.42% and Medina International Holdings, Inc (OTCMKTS: MIHI) sank 50%. However, one of these small caps (Blue Water Global Group) appears to be reversing course in early morning trading today. So with it and the rest of these small cap stocks either sink or swim in trading this week? Here is a closer look to help you decide on an investing or trading strategy:

• [By Peter Graham]

  Small cap stocks Naturalnano Inc (OTCMKTS: NNAN), Global Payout, Inc (OTCMKTS: GOHE) and Blue Water Global Group Inc (OTCBB: BLUU) were either jumping higher or diving lower yesterday. To complicate matters for investors, two of these small cap stocks have been subjects of disclosures about paid promotion or investor relation campaigns. So what will these three small caps do for the rest of this week? Here is a closer look to help you decide on a trading or investing strategy:

Top Diversified Bank Stocks To Buy For 2014: Signature Bank (SBNY)

Signature Bank (the Bank) is a full-service commercial bank with 25 private client offices located in the New York metropolitan area serving the needs of privately owned business clients and their owners and senior managers. The Bank offers a variety of business and personal banking products and services through the Bank, as well as investment, brokerage, asset management and insurance products and services through its wholly owned subsidiary, Signature Securities Group Corporation (Signature Securities), a licensed broker-dealer and investment adviser. Through Signature Securities, it also purchases, securitizes and sells the guaranteed portions of the United States Small Business Administration (SBA) loans. The Bank offers a variety of deposit, escrow deposit, credit, cash management, investment and insurance products and services to its clients. As of December 31, 2011, the Bank maintained approximately 78,000 deposit accounts, 6,900 investment accounts, 8,600 loan accounts and 14,300 client relationships. In April 2012, it formed a new subsidiary, Signature Financial, LLC.

The Bank offers a range of products and services oriented to the needs of its business clients, including deposit products, such as non-interest-bearing checking accounts, money market accounts and time deposits; escrow deposit services; cash management services; commercial loans and lines of credit for working capital and to finance internal growth, acquisitions and leveraged buyouts; permanent real estate loans; letters of credit; investment products to help better manage idle cash balances, including money market mutual funds and short-term money market instruments; business retirement accounts, such as 401(k) plans, and business insurance products, including group health and group life products. It offers a range of products and services oriented to the needs of its high net worth personal clients, including interest-bearing and non-interest-bearing checking accounts, with optional features, such as debit/ autom! ated teller machine (ATM) cards and overdraft protection and, for its clients, rebates of certain charges, including ATM fees; money market accounts and money market mutual funds; time deposits; personal loans, both secured and unsecured; mortgages, home equity loans and credit card accounts; investment and asset management services, and personal insurance products, including health, life and disability.

Lending Activities

The Bank�� commercial and industrial (C&I) loan portfolio is consisted of lines of credit for working capital and term loans to finance equipment, company owned real estate and other business assets, along with commercial overdrafts. Its lines of credit for working capital are generally renewed on an annual basis and its term loans generally have terms of 2 to 5 years. The Bank�� lines of credit and term loans typically have floating interest rates, and as of December 31, 2011, approximately 61% of its outstanding C&I loans were variable rate loans. As of December 31, 2011, funded C&I loans totaled approximately 15% of its total funded loans. The Bank�� real estate loan portfolio includes loans secured by commercial and residential properties. It also provides temporary financing for commercial and residential property. As of December 31, 2011, funded real estate loans totaled approximately $5.74 billion, representing approximately 80% of its total funded loans. It issues standby or performance letters of credit, and can service the international needs of its clients through correspondent banks. As of December 31, 2011, its commitments under letters of credit totaled approximately $235.7 million. Its personal loan portfolio consists of personal lines of credit and loans to acquire personal assets. As of December 31, 2011, its consumer loans totaled $11.8 million, representing less than 1% of its total funded loans.

Investment and Asset Management Products and Services

Investment and asset management products and services are ! provided ! through the Bank�� subsidiary, Signature Securities. Signature Securities is a licensed broker-dealer. Signature Securities is an introducing firm and, as such, clears its trades through National Financial Services, Inc., a wholly owned subsidiary of Fidelity Investments. Signature Securities is also registered as an investment adviser in New York, New Jersey, Pennsylvania and Florida. It offers an array of asset management and investment products, including the ability to purchase and sell all types of individual securities, such as equities, options, fixed income securities, mutual funds and annuities. The Bank offers transactional, cash management type brokerage accounts with check writing and daily sweep capabilities. It also offers retirement products, such as individual retirement accounts (IRAs) and administrative services for retirement vehicles, such as pension, profit sharing, and 401(k) plans to its clients. Signature Securities offers wealth management services to its high net worth personal clients. Together with its client and their other professional advisors, including attorneys and certified public accountants, it develops a financial plan that can include estate planning, business succession planning, asset protection, investment management, family office advisory services, bill payment, art and collectible advisory services and concentrated stock services.

Sources of Funds

The Bank offers a variety of deposit products to its clients. Its business deposit products include commercial checking accounts, money market accounts, escrow deposit accounts, lockbox accounts, cash concentration accounts and other cash management products. Its personal deposit products include checking accounts, money market accounts and certificates of deposit. The Bank also allows its personal and business deposit clients to access their accounts, transfer funds, pay bills and perform other account functions over the Internet and through ATM machines. As of December 31, 2011, it main! tained ap! proximately 78,000 deposit accounts representing $11.70 billion in client deposits, excluding brokered deposits.

Insurance Services

The Bank offers its business and private clients an array of individual and group insurance products, including health, life, disability and long-term care insurance products through its subsidiary, Signature Securities. The Bank does not underwrite insurance policies. It only acts as an agent in offering insurance products and services underwritten by insurers.

Advisors' Opinion:

• [By Ben Levisohn]

  Each month, Credit Suisse’s small-cap strategists ask the firm’s analyst to name their favorite small- and mid-cap stocks. This month, six new stocks made the list: RPM International (RPM), SunCoke Energy (SXC), Zions Bancorp (ZION), Signature Bank (SBNY), Edwards Lifesciences (EW) and�Rexnord (RXN).

Top Diversified Bank Stocks To Buy For 2014: Roche Holding AG (RHHBY)

Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. The Company belongs to the Roche Group that operates through numerous subsidiaries and associated companies located around the world. The Company�� products and services cover every stage of the healthcare process, from identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring. Roche operates through two divisions: Pharmaceuticals and Diagnostics. Within the Pharmaceuticals Division there are three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. The Company�� Diagnostics Division includes five sub-divisions: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan. In March 2009, the Company completed the acquisition of Genentech, Inc. In March 2010, the Company acquired assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow.

During the year ended December 31, 2008, the Company Pharmaceuticals Division marketing gained approvals for its rheumatoid arthritis medicine Actemra/RoActemra in Japan, Switzerland and the European Union. In 2008, the division initiated 12 new phase III projects in, including clinical trials of the compounds pertuzumab, for breast cancer; taspoglutide, for type two diabetes, and dalcetrapib, for cardiovascular risk reduction. As of December 31, 2008, the Pharmaceuticals Division filed 11 major new marketing applications and gained 13 major regulatory approvals. At the beginning of 2009, the division�� research and development pipeline comprised 120 clinical projects, including 62 new molecular entities (NMEs) and 58 additional indications. Forty NMEs are in phase I, 16 in phase II and six in phase III or f! iled for regulatory review.

In 2008, Roche Pharmaceuticals signed a total of 57 new agreements including seven product transactions and 43 research and technology collaborations. In May 2008, Roche acquired Piramed Limited, a UK company with therapeutic research programmes targeting the PI3-kinase pathway in oncology and inflammatory disease. In June 2008, signed licensing agreement with ThromboGenics and BioInvent for their jointly developed anticancer agent TB-403 (R7334). In September, 2008, the Company acquired Mirus Bio Corporation active in the field of ribonucleic acid interference (RNAi) delivery and completed the acquisition of ARIUS Research Inc., which has a antibody platform that identifies and selects antibodies based on their functional ability to affect disease. S Research Inc. In January 2009, Roche acquired Memory Pharmaceuticals, which develops drug candidates for the treatment of debilitating central nervous system disorders such as Alzheimer�� disease and schizophrenia.

Pharmaceuticals

Within Pharmaceuticals division, the Company is engaged in the provision of drugs the areas of oncology, anemia, cardiovascular diseases, central nervous system, infectious diseases, inflammatory and autoimmune diseases, metabolic disorders, cancer, transplantation and virology. The products offered by Roche�� Pharmaceuticals division include MabThera/Rituxan, Herceptin, Avastin, Tamiflu, CellCept, NeoRecormon, Epogin, Pegasys, Tarceva, Xeloda, Bonviva, Boniva, Lucentis, Tamiflu, Xolair, Valcyte, Cymevene, Xenical, Pulmozyme, Nutropin, Neutrogin, Rocephin, Activase, TNKase and Madopar. The products offered by the Pharmaceuticals division are sold in seven geographic regions: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan.

Diagnostics

Roche�� Diagnostics Division is a supplier of in vitro diagnostics (IVDs). Its products are used to test body fluids a! nd tissue! samples to obtain information for the purpose of preventing, diagnosing, treating and monitoring disease. The Company has business areas five within the diagnostics division: Professional Diagnostics, Diabetes Care, Tissue Diagnostics, Molecular Diagnostics and Applied Science. Roche�� Diagnostics division provides IVD services, including centralized laboratory testing and point-of-care diagnostics to molecular diagnostics and diabetes self management. In addition, it supplies research tools to life scientists.

Roche Professional Diagnostics supplies instrument systems, tests, software and services. It provides point-of-care testing products to support clinical decision-making close to the patient, in doctors��offices, emergency rooms and other primary and specialty care settings. Twelve Serum Work Area assays were rolled out during the year ended December 31, 2008, across Europe and in other markets. New assays included the Elecsys anti-TSH receptor antibody assay for the diagnosis of Graves��disease the Elecsys anti-CCP antibody assay, a test to aid the diagnosis of rheumatoid arthritis, and the Roche Cystatin C clinical chemistry test for early detection of impaired kidney function, among others. Roche Diabetes Care�� products portfolio covers the entire diabetes self-management spectrum, from glucose monitoring to insulin delivery, as well as monitoring systems with integrated lancets and test strips software for storing and analyzing data. Roche Tissue Diagnostics develops and manufactures medical diagnostic instruments and reagent systems that provide automation technology for use in the diagnosis and prognosis of cancer and infectious disease. In 2008 Roche Tissue Diagnostics launched ofhe Bench- Mark Ultra, a system that performs immunohistochemistry and in situ hybridisation testing simultaneously on a single continuous and random access platform. Roche Molecular Diagnostics develops and commercializes diagnostic and blood screening platforms and tests based on Roche�� ! real-time! polymerase chain reaction (PCR) technology. Applied Science business area supplies a specific reagents and test kits for use in life sciences encompassing biology, biotechnology ,medical research, as well as disease areas like cancer and virology. Applied Science�� business area product portfolio includes such sequencing systems as LightCycler 480, LightCycler 480 II, GS FLX Titanium. In addition, Applied Science offers xCELLigence cell analyzer.

Advisors' Opinion:

• [By Sean Williams]

  Dendreon's likely partner
  While it's purely speculation on my part, I believe the most likely marketing partner would be one of Europe's premier cancer-fighting companies, Roche (NASDAQOTH: RHHBY  ) .